TY - JOUR
T1 - Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe
T2 - the PanCareSurFup study
AU - Sunguc, Ceren
AU - Hawkins, Michael M.
AU - Winter, David L.
AU - Dudley, Isabelle M.
AU - Heymer, Emma J.
AU - Teepen, Jop C.
AU - Allodji, Rodrigue S.
AU - Belle, Fabiën N.
AU - Bagnasco, Francesca
AU - Byrne, Julianne
AU - Bárdi, Edit
AU - Ronckers, Cécile M.
AU - Haddy, Nadia
AU - Gudmundsdottir, Thorgerdur
AU - Garwicz, Stanislaw
AU - Jankovic, Momcilo
AU - van der Pal, Helena J.H.
AU - Mazić, Maja Česen
AU - Schindera, Christina
AU - Grabow, Desiree
AU - Maule, Milena M.
AU - Kaatsch, Peter
AU - Kaiser, Melanie
AU - Fresneau, Brice
AU - Michel, Gisela
AU - Skinner, Roderick
AU - Wiebe, Thomas
AU - Sacerdote, Carlotta
AU - Jakab, Zsuzsanna
AU - Gunnes, Maria Winther
AU - Terenziani, Monica
AU - Winther, Jeanette F.
AU - Lähteenmäki, Päivi M.
AU - Zaletel, Lorna Zadravec
AU - Kuehni, Claudia E.
AU - Kremer, Leontien C.
AU - Haupt, Riccardo
AU - de Vathaire, Florent
AU - Hjorth, Lars
AU - Reulen, Raoul C.
N1 - © 2022. The Author(s).
PY - 2023/1
Y1 - 2023/1
N2 - Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results: One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6–25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3–44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6–23.7). Conclusions: Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early.
AB - Background: Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods: The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results: One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6–25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3–44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6–23.7). Conclusions: Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early.
UR - http://www.scopus.com/inward/record.url?scp=85141153732&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/d1be9f55-c336-3544-917f-d9f653340b91/
U2 - 10.1038/s41416-022-02016-w
DO - 10.1038/s41416-022-02016-w
M3 - Article
C2 - 36319851
AN - SCOPUS:85141153732
SN - 0007-0920
VL - 128
SP - 80
EP - 90
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 1
ER -